These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34562464)

  • 1. Inclusion of Under-represented Racial and Ethnic Minorities in Randomized Clinical Trials for Inflammatory Bowel Disease.
    Cohen NA; Silfen A; Rubin DT
    Gastroenterology; 2022 Jan; 162(1):17-21. PubMed ID: 34562464
    [No Abstract]   [Full Text] [Related]  

  • 2. Underrepresentation of Minorities and Underreporting of Race and Ethnicity in Crohn's Disease Clinical Trials.
    Sedano R; Hogan M; Mcdonald C; Aswani-Omprakash T; Ma C; Jairath V
    Gastroenterology; 2022 Jan; 162(1):338-340.e2. PubMed ID: 34592174
    [No Abstract]   [Full Text] [Related]  

  • 3. Underrepresentation of Ethnic and Racial Minorities in Atrial Fibrillation Clinical Trials.
    Nunes JC; Rice EN; Stafford RS; Lewis EF; Wang PJ
    Circ Arrhythm Electrophysiol; 2021 Dec; 14(12):e010452. PubMed ID: 34789014
    [No Abstract]   [Full Text] [Related]  

  • 4. Diversity and Inclusion in Pancreatic Cancer Clinical Trials.
    Herremans KM; Riner AN; Winn RA; Trevino JG
    Gastroenterology; 2021 Dec; 161(6):1741-1746.e3. PubMed ID: 34416276
    [No Abstract]   [Full Text] [Related]  

  • 5. Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to?
    Gearry RB; Irving PM
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1160-2. PubMed ID: 19682189
    [No Abstract]   [Full Text] [Related]  

  • 6. Tofacitinib, two-faced Janus in ulcerative colitis and Crohn's disease?
    Biemans VB; Verstockt B
    United European Gastroenterol J; 2020 Aug; 8(7):753-754. PubMed ID: 32640933
    [No Abstract]   [Full Text] [Related]  

  • 7. Vedolizumab for the treatment of ulcerative colitis.
    Shahidi N; Bressler B; Panaccione R
    Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing disease activity and disease activity indices for inflammatory bowel disease.
    Xiao Li F; Sutherland LR
    Curr Gastroenterol Rep; 2002 Dec; 4(6):490-6. PubMed ID: 12441039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How Failure Can Fuel Improvements in Early Drug Development for Inflammatory Bowel Diseases.
    Schreiber S; Vermeire S
    Gastroenterology; 2016 May; 150(5):1061-1066. PubMed ID: 27018485
    [No Abstract]   [Full Text] [Related]  

  • 10. An evidence-based systematic review on medical therapies for inflammatory bowel disease.
    Talley NJ; Abreu MT; Achkar JP; Bernstein CN; Dubinsky MC; Hanauer SB; Kane SV; Sandborn WJ; Ullman TA; Moayyedi P;
    Am J Gastroenterol; 2011 Apr; 106 Suppl 1():S2-25; quiz S26. PubMed ID: 21472012
    [No Abstract]   [Full Text] [Related]  

  • 11. Methotrexate for inflammatory bowel disease: time for reconsideration.
    Nielsen OH; Ainsworth MA; Steenholdt C
    Expert Rev Gastroenterol Hepatol; 2019 May; 13(5):407-409. PubMed ID: 30895827
    [No Abstract]   [Full Text] [Related]  

  • 12. Underrepresentation of Minorities and Lack of Race Reporting in Ulcerative Colitis Drug Development Clinical Trials.
    Sedano R; Hogan M; McDonald C; Aswani-Omprakash T; Ma C; Jairath V
    Inflamm Bowel Dis; 2022 Aug; 28(8):1293-1295. PubMed ID: 35078220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world evidence for vedolizumab: Understanding the landscape.
    Lawrance IC; Pulusu SSR
    J Gastroenterol Hepatol; 2018 Sep; 33 Suppl 3():28-29. PubMed ID: 30187556
    [No Abstract]   [Full Text] [Related]  

  • 14. [Chronic inflammatory bowel diseases. Strive for healing the mucosa, prevent overtreatment].
    MMW Fortschr Med; 2014 Jul; 156(13):64-5. PubMed ID: 25318230
    [No Abstract]   [Full Text] [Related]  

  • 15. Bezlotoxumab for Clostridium difficile Infection Complicating Inflammatory Bowel Disease.
    Kelly CP; Wilcox MH; Glerup H; Aboo N; Ellison MC; Eves K; Dorr MB
    Gastroenterology; 2018 Oct; 155(4):1270-1271. PubMed ID: 30227108
    [No Abstract]   [Full Text] [Related]  

  • 16. [Inflammatory bowel diseases].
    MMW Fortschr Med; 2013 Nov; 155 Spec No 2():56-60; quiz 61. PubMed ID: 24734460
    [No Abstract]   [Full Text] [Related]  

  • 17. [Crohn disease and ulcerative colitis. Aggressive early therapy is effective].
    Kreutzkamp B
    MMW Fortschr Med; 2009 Nov; 151(45):20. PubMed ID: 19960717
    [No Abstract]   [Full Text] [Related]  

  • 18. THE APPROVAL OF VEDOLIZUMAB FOR THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES IN BRAZIL: the beginning of a new biological era.
    Kotze PG; Damião AO; Moraes AC
    Arq Gastroenterol; 2016; 53(1):3-4. PubMed ID: 27276096
    [No Abstract]   [Full Text] [Related]  

  • 19. Recommendations for inflammatory bowel disease.
    LaMont JT
    Geriatrics; 1982 Mar; 37(3):93-6, 102, 105. PubMed ID: 6802705
    [No Abstract]   [Full Text] [Related]  

  • 20. Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design.
    Abreu MT; Sandborn WJ;
    Gastroenterology; 2020 Dec; 159(6):2013-2018.e7. PubMed ID: 32961246
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.